Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of nivolumab for melanoma that can't be removed with surgery or has spread to other parts of the body (CheckMate 067)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at a drug called nivolumab for melanoma that can’t be removed or has spread to another part of the body. If melanoma can’t be removed with surgery or has spread to another part of your body, it is called advanced melanoma.
More about this trial
- See which treatment works best
- Learn more about the side effects
Summary of results
- 315 had ipilimumab
- 316 had nivolumab
- 345 had nivolumab and ipilimumab
- just under 3 months (2.9 months) in the group who had ipilimumab
- just under 7 months (6.9 months) in the group who had nivolumab
- 11 ½ months in the group who had nivolumab and ipilimumab
- just under 3 out of 10 people (26%) who had ipilimumab
- just over 4 out of 10 people (44%) who had nivolumab
- just over 5 out of 10 people (52%) who had nivolumab and ipilimumab
- tiredness (fatigue)
- a rash
- liver damage
How to join a clinical trial
Dr James Larkin
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer